ATG-017 in Combination Therapy for Advanced Solid Tumor and Hematological Malignancies
Unknown Phase 1 NCT04305249
Study Description
This phase I clinical trial study examines the safety and efficacy of ATG-017 administered orally alone or in conjunction with nivolumab in patients with advanced solid tumors and hematological malignancies. The study encompasses two modules, ATG-017 monotherapy, and the combination of ATG-017 with nivolumab. Both modules include a dose escalation phase, followed by a dose expansion phase. The dose escalation of ATG 017 will be conducted with safety monitoring to ensure the safety of patients. The study will evaluate the optimal dose level and schedule for both continuous and intermittent dosing.
Study Details
- Registry ID:
- NCT04305249
- Conditions:
- Solid Tumor, Hematological Malignancy
- Phase:
- Phase 1
- Target Enrollment:
- 36 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (7 sites)
-
Alfred Hospital
Melbourne, Victoria, Australia -
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia -
Austin Hospital
Heidelberg, Victoria, Australia -
Chris O'Brien Lifehouse
Sydney, Australia -
Chris O'Brien Lifehouse
Sydney, New South Wales, Australia -
Scientia Clinical Research
Randwick, Australia -
Scientia Clinical Research
Randwick, New South Wales, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.